Arxx Therapeutics is a biotechnology company focused on the development of innovative treatments for fibrosis. The company works with a ground-breaking monoclonal antibody therapy that has a unique mechanism of action. This approach targets non-resolving tissue fibrosis, a condition that can lead to significant health problems.
The company's research aims to improve treatment options for patients suffering from fibrosis, a condition in which connective tissue becomes abnormally thickened. Arxx Therapeutics' work can potentially help change the treatment landscape in this field, and their focus on monoclonal antibodies represents a new direction in biotechnology.
